NEW YORK STATE COMMON RETIREMENT FUND - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.

Quarter-by-quarter ownership
NEW YORK STATE COMMON RETIREMENT FUND ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$37,054
+8.2%
969,999
+2.2%
0.05%
+20.5%
Q2 2023$34,244
+8.3%
949,387
+14.6%
0.04%
+4.8%
Q1 2023$31,631
-30.5%
828,250
+3.5%
0.04%
-32.3%
Q4 2022$45,525
-99.9%
800,091
-16.4%
0.06%
+12.7%
Q3 2022$37,860,000
-11.5%
957,511
-1.5%
0.06%
-1.8%
Q2 2022$42,777,000
-0.2%
972,197
-9.6%
0.06%
+21.7%
Q1 2022$42,870,000
-15.3%
1,074,977
-14.6%
0.05%
-9.8%
Q4 2021$50,642,000
-28.8%
1,259,450
-28.0%
0.05%
-32.9%
Q3 2021$71,162,000
-3.0%
1,749,309
+8.3%
0.08%0.0%
Q2 2021$73,352,000
+4.8%
1,615,323
-3.7%
0.08%
-1.3%
Q1 2021$69,962,000
+2.5%
1,678,138
+5.1%
0.08%
+1.3%
Q4 2020$68,224,000
+56.2%
1,597,382
-3.9%
0.08%
+43.4%
Q3 2020$43,668,000
-2.0%
1,661,6560.0%0.05%
-7.0%
Q2 2020$44,549,000
+61.0%
1,661,656
+8.0%
0.06%
+35.7%
Q1 2020$27,678,000
+77.8%
1,538,499
+75.2%
0.04%
+121.1%
Q4 2019$15,567,000
-2.5%
878,019
-14.7%
0.02%
-5.0%
Q3 2019$15,967,000
+2.4%
1,029,443
+13.5%
0.02%0.0%
Q2 2019$15,588,000
-1.0%
907,353
-7.3%
0.02%0.0%
Q1 2019$15,753,000
+2.7%
978,449
-6.6%
0.02%
-9.1%
Q4 2018$15,333,000
-17.2%
1,048,054
+2.9%
0.02%0.0%
Q3 2018$18,511,000
+19.7%
1,018,770
+11.1%
0.02%
+15.8%
Q2 2018$15,468,000
-10.1%
916,884
+4.4%
0.02%
-9.5%
Q1 2018$17,208,000
+0.4%
878,396
+3.8%
0.02%0.0%
Q4 2017$17,137,000
+17.4%
845,875
+0.7%
0.02%
+10.5%
Q3 2017$14,596,000
+51.8%
840,284
+12.0%
0.02%
+46.2%
Q2 2017$9,616,000
+9.4%
750,041
+10.6%
0.01%
+8.3%
Q1 2017$8,788,000
+81.9%
678,108
+38.7%
0.01%
+71.4%
Q4 2016$4,831,000
-5.3%
488,940
+15.8%
0.01%0.0%
Q3 2016$5,102,000
+54.5%
422,340
+10.4%
0.01%
+40.0%
Q2 2016$3,302,000
-8.3%
382,670
+0.6%
0.01%
-16.7%
Q1 2016$3,601,000
-44.3%
380,290
+2.0%
0.01%
-40.0%
Q4 2015$6,460,000
+35.9%
372,785
+5.4%
0.01%
+25.0%
Q3 2015$4,752,000
-49.0%
353,845
-14.3%
0.01%
-42.9%
Q2 2015$9,322,000
+136.4%
412,835
+49.5%
0.01%
+133.3%
Q1 2015$3,943,000276,1300.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders